Prana Biotechnology secures FDA orphan drug status for PBT434 to treat multiple system atrophy
In a significant milestone, Prana Biotechnology, an Australian biotech company, has obtained Orphan Drug designation from the FDA for PBT434, its lead molecule aimed at treating Multiple System Atrophy (MSA), a rare and degenerative neurological disease. This designation offers Prana Biotechnology substantial regulatory advantages, such as seven years of market exclusivity and access to tax […]